159 related articles for article (PubMed ID: 23644715)
21. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
22. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.
Wahl RL; Cody RL; Hutchins GD; Mudgett EE
Radiology; 1991 Jun; 179(3):765-70. PubMed ID: 2027989
[TBL] [Abstract][Full Text] [Related]
23. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies.
Torizuka T; Zasadny KR; Recker B; Wahl RL
Radiology; 1998 Jun; 207(3):767-74. PubMed ID: 9609902
[TBL] [Abstract][Full Text] [Related]
24. Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model.
Zhang Y; Saylor M; Wen S; Silva MD; Rolfe M; Bolen J; Muir C; Reimer C; Chandra S
Mol Imaging Biol; 2006; 8(5):300-8. PubMed ID: 16897318
[TBL] [Abstract][Full Text] [Related]
25. Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging.
Simons AL; Fath MA; Mattson DM; Smith BJ; Walsh SA; Graham MM; Hichwa RD; Buatti JM; Dornfeld K; Spitz DR
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1222-30. PubMed ID: 17967311
[TBL] [Abstract][Full Text] [Related]
26. Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer.
Tchou J; Sonnad SS; Bergey MR; Basu S; Tomaszewski J; Alavi A; Schnall M
Mol Imaging Biol; 2010 Dec; 12(6):657-62. PubMed ID: 20012701
[TBL] [Abstract][Full Text] [Related]
27. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy.
Sugawara Y; Fisher SJ; Zasadny KR; Kison PV; Baker LH; Wahl RL
J Clin Oncol; 1998 Jan; 16(1):173-80. PubMed ID: 9440740
[TBL] [Abstract][Full Text] [Related]
28. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
29. Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity.
Schillaci O
Semin Nucl Med; 2012 Jul; 42(4):267-80. PubMed ID: 22681676
[TBL] [Abstract][Full Text] [Related]
30. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
31. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
32. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
[TBL] [Abstract][Full Text] [Related]
33. The Structural Basis of Action of Vanadyl (VO
Makinen MW; Salehitazangi M
Coord Chem Rev; 2014 Nov; 279():1-22. PubMed ID: 25237207
[TBL] [Abstract][Full Text] [Related]
34. PET Imaging of
Liu F; Xu X; Zhu H; Zhang Y; Yang J; Zhang L; Li N; Zhu L; Kung HF; Yang Z
Mol Pharm; 2018 Aug; 15(8):3448-3455. PubMed ID: 29985631
[TBL] [Abstract][Full Text] [Related]
35. Newly-Developed Positron Emission Mammography (PEM) Device for the Detection of Small Breast Cancer.
Yanai A; Itoh M; Hirakawa H; Yanai K; Tashiro M; Harada R; Yoshikawa A; Yamamoto S; Ohuchi N; Ishida T
Tohoku J Exp Med; 2018 May; 245(1):13-19. PubMed ID: 29731479
[TBL] [Abstract][Full Text] [Related]
36. Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab.
Cheyne RW; Trembleau L; McLaughlin A; Smith TA
Nucl Med Biol; 2011 Apr; 38(3):339-46. PubMed ID: 21492782
[TBL] [Abstract][Full Text] [Related]
37. Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2.
Kang F; Ma W; Ma X; Shao Y; Yang W; Chen X; Li L; Wang J
J Nucl Med; 2014 Mar; 55(3):439-45. PubMed ID: 24504055
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings.
Crowe JP; Adler LP; Shenk RR; Sunshine J
Ann Surg Oncol; 1994 Mar; 1(2):132-40. PubMed ID: 7834438
[TBL] [Abstract][Full Text] [Related]
39. Efficient Synthesis and HPLC-Based Characterization for Developing Vanadium-48-Labeled Vanadyl Acetylacetonate as a Novel Cancer Radiotracer for PET Imaging.
Broder BA; Bhuiyan M; Freifelder R; Rotsch DA; Chitneni SK; Makinen MW; Chen CT
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398551
[No Abstract] [Full Text] [Related]
40. Dynamic 2-Deoxy-2-[
Kristian A; Holtedahl JE; Torheim T; Futsaether C; Hernes E; Engebraaten O; Mælandsmo GM; Malinen E
Mol Imaging Biol; 2017 Apr; 19(2):271-279. PubMed ID: 27541026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
